Garnier L F
Service de Cardiologie, Centre Hospitalier, Vendôme.
Ann Cardiol Angeiol (Paris). 1997 Oct;46(8):507-12.
The clinical benefit of aspirin in coronary insufficiency has been validated in the acute phase of myocardial infarction and in secondary prevention with a reduction of the risk of recurrent infarction of the order of 30%. By interfering with the process of thrombolysis, aspirin modifies the natural history of coronary artery disease by decreasing the frequency and severity of pathological events. Although a relative consensus has been reached concerning the dosages (160 to 325 mg/day), the use of aspirin nevertheless remains very insufficient, sometimes because of the risk of gastrointestinal intolerance related to the gastrotoxicity of aspirin, hence the importance of pharmaceutical forms designed to improve the gastrointestinal tolerance, such as calcium carbasalate (soluble aspirin complex), which appears to be particularly well tolerated.
阿司匹林在冠状动脉功能不全中的临床益处已在心肌梗死急性期和二级预防中得到验证，可将复发性梗死风险降低约30%。通过干扰溶栓过程，阿司匹林通过降低病理事件的频率和严重程度来改变冠状动脉疾病的自然病程。尽管在剂量（160至325毫克/天）方面已达成相对共识，但阿司匹林的使用仍然非常不足，有时是因为与阿司匹林的胃毒性相关的胃肠道不耐受风险，因此旨在提高胃肠道耐受性的药物剂型很重要，例如卡巴匹林钙（可溶性阿司匹林复合物），它似乎耐受性特别好。
